| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/CJI.0B013E31825898E8 |
| P8608 | Fatcat ID | release_smdyxkpohjcwvjdkwersrxsjra |
| P932 | PMC publication ID | 3358728 |
| P698 | PubMed publication ID | 22576348 |
| P5875 | ResearchGate publication ID | 224939601 |
| P50 | author | Steven Rosenberg | Q2347448 |
| Hui Xu | Q110142739 | ||
| P2093 | author name string | Ling Zhang | |
| Richard A Morgan | |||
| Zhili Zheng | |||
| Mark E Dudley | |||
| Steven A Feldman | |||
| Nachimuthu Chinnasamy | |||
| Azam V Nahvi | |||
| P2860 | cites work | Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens | Q24644442 |
| Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts | Q34109953 | ||
| Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients | Q34111120 | ||
| CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma | Q34299986 | ||
| Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells | Q34519488 | ||
| Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions | Q34669675 | ||
| Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment | Q34757266 | ||
| Evaluation of residual promoter activity in γ-retroviral self-inactivating (SIN) vectors | Q35665234 | ||
| Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity | Q35849232 | ||
| Adoptive cell transfer therapy | Q36380249 | ||
| Interleukin-12: biological properties and clinical application | Q36910729 | ||
| Expression levels of the PiT-2 receptor explain, in part, the gestational age-dependent alterations in transduction efficiency after in utero retroviral-mediated gene transfer | Q37602026 | ||
| Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors | Q40150079 | ||
| A Simple and Reliable Method for Screening Retroviral Producer Clones Without Selectable Markers | Q41102466 | ||
| The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells | Q41736991 | ||
| Gene therapy for SCID-X1: round 2 | Q42346429 | ||
| Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. | Q45858725 | ||
| IL-12 deaths: explanation and a puzzle | Q71542131 | ||
| Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production | Q73774733 | ||
| NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells | Q73971391 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 430-439 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | Journal of Immunotherapy | Q15763946 |
| P1476 | title | Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application | |
| P478 | volume | 35 |
| Q38170496 | Adoptive immunotherapy for cancer. |
| Q48648729 | Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18. |
| Q26745600 | CAR models: next-generation CAR modifications for enhanced T-cell function |
| Q38913549 | Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You. |
| Q48337005 | Chimeric antigen receptor transduced T cells: Tuning up for the next generation |
| Q28269352 | Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance |
| Q89436068 | Continuous production process of retroviral vector for adoptive T- cell therapy |
| Q36755385 | Engineered T cells for anti-cancer therapy. |
| Q39232187 | Enhanced IL-12p40 production in LPS-stimulated macrophages by inhibiting JNK activation by artemisinin |
| Q92782148 | Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models |
| Q37576033 | Exploiting the curative potential of adoptive T-cell therapy for cancer |
| Q64266371 | Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors |
| Q46507832 | Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting |
| Q91964127 | Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy |
| Q26741260 | Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors |
| Q26781432 | Progresses towards safe and efficient gene therapy vectors |
| Q26766184 | Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells |
| Q91272172 | Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality |
| Q39264898 | Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities |
| Q38488557 | TRUCKs: the fourth generation of CARs |
| Q92542097 | Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells |
| Q35613148 | Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma |
Search more.